CPT code 0166U denotes the LiverFASt™ Proprietary Laboratory Analyses (PLA) test from Fibronostics, a blood‑based panel that measures 10 liver‑related biomarkers and uses a proprietary algorithm to estimate fibrosis stage, steatosis, and inflammatory activity without invasive procedures. As a PLA code, 0166U is unique to a single manufacturer's test and signals to payers and providers that the service includes both biomarker measurement and algorithmic interpretation.

Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and coding policies for PLA tests can vary by payer; PLA codes are intended to improve transparency for novel, proprietary diagnostics and to facilitate payer review of clinical validity and utility.

Readers will find a concise overview of the clinical purpose of the test, the service setting for specimen collection and laboratory processing, and what payers typically consider when evaluating coverage for proprietary diagnostic algorithms. The publication also summarizes common billing considerations, including the PLA code designation and how that designation affects payer review processes. Data not available in the input: detailed payer policy language, reimbursement benchmarks, associated taxonomies, and specific ICD‑10 diagnoses tied to billing for this test.